Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jimmy Faivre has a total of 98 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Achieving High Projection Without Compromise: Process Optimization of a New Resilient Hyaluronic Acid for Deep Structural Support

    by Jimmy Faivre, Killian Flégeau, Camille Vantou, Alice Melotti, Elodie Clerc, François Bourdon

    Background: Traditional technology used to create cohesive hyaluronic acid (HA) injectables for aesthetic use often relies on increased HA concentration and high crosslinking to maximize strength and robustness. As a result, natural HA integrity may be compromised, leading to less dynamic rheology, difficulty in hyaluronidase degradation, and poor tissue integration. Objectives: The aim of this study was to demonstrate high projection capability, reversibility, and smooth tissue integration with an HA injectable gel produced from an optimized crosslinking process without high 1,4-butanediol diglycidyl ether modification. Methods: TPVM was created using optimized Preserved Network Technology (PNT+) crosslinking technology and evaluated against the existing US-approved and Conformité Européenne (CE)-marked resilient hyaluronic acid (RHA) fillers (RHA1-RHA4 in Europe, RHA Redensity, RHA2-3, and RHA Dynamic Volume in the United States). Assessments included physicochemical properties, rheology, injectability, hyaluronidase degradation, physician-rated injection ease across 3 indications, and long-term tissue integration in minipigs up to 156 weeks. Results: Despite a modification degree of 2.1%, among the lowest in the marketed fillers, TPVM achieved the highest elastic modulus (G′ = 629 ± 8 Pa), linear viscoelastic region (454 ± 15 Pa), and resistance to compression force (10.5 ± 0.1 N). Injectability was rated “very easy” or “easy” in over 94% of cases across midface, chin retrusion, and jawline indications. Like all RHA gels, TPVM reached complete hyaluronidase degradation within 30 min. Histological evaluation at 52 and 156 weeks confirmed smooth tissue integration and progressive gel degradation with no encapsulation or persistent inflammation. Conclusions: Optimized PNT+ crosslinking technology decouples gel mechanical performance from the degree of chemical modification, enabling superior projection capacity while preserving enzymatic reversibility and tissue integration.

  • Native Chemical Ligation-Driven Formation of Hyaluronic Acid-Based Injectable Hydrogels

    by Camille Vantou, Nolwenn Vigneron, Benoit Keromnes, Romain Brusini, Michel Marquet, FrançoIs Bourdon, SébAstien Vidal, Jimmy Faivre

    We report the development of an injectable hyaluronic acid (HA)-based hydrogel using native chemical ligation (NCL) as a biocompatible and chemoselective crosslinking strategy for potential biomedical applications. High-molecular-weight HA was pre-modified with a glycinyl thioester derivative, while a bis-cysteine peptide served as the crosslinker, enabling rapid hydrogel formation under physiological conditions. After optimization of NCL parameters, the resulting hydrogel exhibits all key attributes for biomedical hydrogel injectables: cytocompatibility, injectability, tunable rheology adapted for soft-tissue delivery (e.g., skin and subcutaneous tissue), enzymatic degradability by hyaluronidase, adjustable swelling, and long-term shelf-life stability. It can be sterilized by autoclaving for injection purposes and also functions as a drug delivery matrix for localized, in situ release. This study presents a robust and scalable HA-based platform, available as either an injectable hydrogel or an in situ cross-linkable solution, with broad potential in drug delivery, regenerative medicine, and aesthetic applications.

  • Open Access

    Crosslinked HA in Topical Application: The Biological Benefits of RHA Serum on Aging Signs

    by Romain Brusini, Laure Peslerbe, Camille Vantou, Pauline Meriaux, Lesley Rose Clark‐Loeser, Jimmy Faivre

    Background: RHA Serum is a topical formulation with proven benefits on skin hydration and biomechanical properties. This study aims to evaluate its role in remodeling the extracellular matrix by stimulating the production of endogenous hyaluronic acid and collagens, thereby supporting its clinical efficacy in reducing visible signs of aging. Methods: Anti‐aging effects were assessed using ex vivo human skin explants and a 56‐day, split‐face, randomized clinical study. Abdominoplasty‐derived human skin explants were treated with RHA Serum or controls and analyzed histologically and immunohistochemically for HA and collagen types I and IV expression. In parallel, 22 women aged 40–65 years applied RHA Serum or placebo daily. Skin thickness and dermal density were measured by high‐frequency ultrasound, while skin quality parameters were quantified using Visia digital imaging. Results: Ex vivo analysis revealed significantly increased expression of HA and collagens I and IV in RHA Serum‐treated samples. In vivo, RHA Serum significantly improved dermal density and epidermal thickness compared to a placebo cream. Visia analysis further confirmed visible reductions in facial wrinkles and skin roughness, aligning with biological improvements observed ex vivo. Conclusion: RHA Serum supports skin structure by promoting key extracellular matrix components, including collagens and endogenous HA. These biological effects translate into measurable clinical improvements. The findings support RHA Serum as a potent, evidence‐based anti‐aging topical treatment.

  • Développement de liquides synoviaux synthétiques bioinspirés

    by Jimmy Faivre

    La bioinspiration consiste à analyser les systèmes naturels qui se sont adaptés parfaitement à leurs environnements pour développer des solutions ingénieuses. Ce projet de thèse aborde la thématique de la lubrification articulaire dans le but de développer un traitement contre l'ostéoarthrite (OA). Nous nous sommes inspirés des articulations synoviales, systèmes tribologiques très performants grâce aux interactions synergiques entre la structure unique du cartilage et les molécules lubrifiantes (ML) du fluide synovial (SF). Cependant, lors de l'OA des mécanismes inflammatoires et d'érosion mécanique aboutissent à la dégénérescence progressive du cartilage et la dégradation spécifique des ML du SF (aggrécane et lubricine). Des mimes des ML du SF ont été synthétisés reprenant leur structure particulière dite en écouvillon moléculaire (BB), structure responsable de la lubrification. Des tests tribologiques (SFA, tribomètre) ont montré que les BB garantissent à la fois une faible friction et une résistance à l'usure sur des surfaces dures de mica. Ceci est dû à la présence, sur nos EM, de groupements d'ancrage spécifiques assurant l’adsorption sur la surface de mica et à la formation d'enchevêtrements et d’interactions intermoléculaires avec l'acide hyaluronique de haut poids moléculaire, composant essentiel du SF. Des mimes de cartilage à base d'hydrogels de chitosane multicouches ont été également réalisés reprenant les principales propriétés architecturales du cartilage. En combinaison avec nos EM, ces hydrogels, matériaux poroélastiques fragiles, sont capables d’être lubrifiés avec une friction dans la gamme physiologique et une nette amélioration de leur usure

  • Open Access

    Non-Crosslinked Hyaluronic Acid Redensity 1® Supports Cell Viability, Proliferation, and Collagen Deposition in Early Burn Management

    by Zhifeng Liao, Xi Chen, Romain Brusini, Jimmy Faivre, Lee Ann Applegate, Killian Flegeau, Nathalie Hirt-Burri

    Background/Objectives: Burn injuries pose a significant challenge due to tissue damage and impaired healing. Cell-based therapies offer promise by delivering therapeutic cells to the wound site. However, effective cell delivery remains a critical hurdle. This study investigates the potential of non-crosslinked hyaluronic acid (HA) as a simple, versatile carrier for delivering autologous keratinocytes and fibroblasts to treat early burn wounds. Methods: Primary keratinocytes and fibroblasts were isolated from uninjured adult skin. In addition, fibroblasts and adipose stem cells (ASC) from polydactyly and progenitor fibroblasts were used. Non-cross-linked HA Redensity 1® (RD1) solutions of varying concentrations were prepared and applied to various in vitro models. Cell viability, proliferation, migration, and collagen stimulation were assessed using standard assays. Additionally, cells were suspended in Redensity 1 and applied to an in vitro de-epidemalized dermis (DED) wound model to examine cell delivery and tissue reformation. Results: Preliminary data demonstrated the feasibility of using non-cross-linked HA RD1 gel as a cell carrier. RD1 gel enhanced cell viability, retention, migration, and collagen deposition. Histological analysis revealed improved cell adhesion and migration. Conclusions: This study provides valuable insight into the potential of non-cross-linked HA RD1 as a simple and effective delivery vehicle for cell therapies in early burn care. Successful translation of this approach could significantly improve clinical outcomes for burn patients.


  • Open Access

    Non-Crosslinked Hyaluronic Acid Redensity 1® Supports Cell Viability, Proliferation, and Collagen Deposition in Early Burn Management

    by Zhifeng Liao, Xi Chen, Romain Brusini, Jimmy Faivre, Lee Ann Applegate, Killian Flegeau, Nathalie Hirt-Burri

    Background/Objectives: Burn injuries pose a significant challenge due to tissue damage and impaired healing. Cell-based therapies offer promise by delivering therapeu-tic cells to the wound site. However, effective cell delivery remains a critical hurdle. This study investigates the potential of non-cross-linked hyaluronic acid (HA) as a simple and versatile carrier for delivering autologous keratinocytes and fibroblasts to treat early burn wounds. Methods: Primary keratinocytes and fibroblasts were isolated from uninjured adult skin. In addition, fibroblasts and adipose stem cells (ASC) from polydactyly and progenitor fibroblasts were used. Non-cross-linked HA Redensity 1® (RD1) solutions of varying concentrations were prepared and applied on various in vitro models. Cell viabil-ity, proliferation, migration and collagen stimulation were assessed using standard as-says. Additionally, cells were suspended in Redensity 1 and applied a the in vitro de-epidemalized dermis (DED) wound model to examine cell delivery and tissue refor-mation. Results: Preliminary data demonstrated the feasibility of using non-cross-linked HA RD1 gel as a cell carrier. RD1 gel enhanced cell viability, retention, migration and col-lagen deposition. Histological analysis revealed improved cell adhesion and migration. Conclusions: This study provides valuable insight into the potential of non-cross-linked HA RD1 as a simple and effective delivery vehicle for cell therapies in early burn care. Successful translation of this approach could significantly improve clinical outcomes for burn patients.

  • Open Access

    Vascular benefit of the use of mepivacaine as an anaesthetic in resilient hyaluronic acid® injectables

    by Jimmy Faivre, Romain Brusini, Jing Jing, Sabrina Walley, Lukas Roubenne, François Bourdon, Lee Walker, Bruno Le Grand, Conor J. Gallagher

    Lidocaine (0.3% w/w) has long been used in HA-based injectables for pain relief, but mepivacaine may be a better alternative, offering similar efficacy without vasodilation, potentially lowering the risk of adverse events.


  • Open Access

    Safety and Performance of RHA4 in the Midface Using the Multilayering Technique: Preclinical and Clinical Evidence

    by Killian Flégeau, Stefania Ballarini, Romain Brusini, Camille Meng Vantou, Zhifeng Liao, Nathalie Hirt-Burri, François Meng Bourdon, Fang-Wen Tseng, Jimmy Faivre

    Background: Resilient hyaluronic acid (RHA) fillers are used to treat dynamic wrinkles or provide tissue lifting in facial aesthetics. This study explored the biological, biomechanical, and clinical safety and performance of RHA4, a volumizing hyaluronic acid filler tailored for tissue support in dynamic facial areas, upon interaction with human subcutaneous adipose tissue (AT). Methods: RHA4 underwent cytocompatibility testing with human fibroblasts and adipose stem cells. A 1-year rat in vivo implantation study tracked tissue integration, local effects, and filler degradation. Biomechanical tests assessed RHA4’s impact on subcutaneous AT mechanics. Clinical outcomes, safety, injection volumes, and techniques were evaluated in 35 patients, treated in midface deep and superficial fat compartments via a multilayering methodology. Dynamic outcomes and 2-year follow-up of RHA4 in the midface using multilayer treatments were described. Results: RHA4 demonstrated excellent biocompatibility and tissue integration both in vitro and in vivo, exhibiting minimal local inflammation and rapid collagen bundle formation within the filler. It integrated gradually over time and was well tolerated, allowing for increased extracellular matrix presence, neovascularization, denser collagen deposition, and AT growth. Ex vivo, RHA4 did not impede fat motion biomechanics but visibly lifted the tissue. Clinically, RHA4 proved safe and effective for lifting both deep and superficial fat compartments in the midface without affecting facial expressiveness. Conclusions: Preclinical and clinical evidence confirmed that RHA4 is a versatile filler capable of lifting tissue efficiently, whether deep or superficial, particularly through the multilayering treatment approach. Importantly, RHA4 preserves AT biomechanics, adapts to the dynamism of the face, and ensures natural-looking outcomes.


  • Open Access

    Comparison of Hyaluronidase-Mediated Degradation Kinetics of Commercially Available Hyaluronic Acid Fillers In Vitro

    by Jimmy Faivre, Kevin Wu, Mélanie Gallet, Julia Sparrow, François Bourdon, Conor J Gallagher

    The ability to degrade hyaluronic acid (HA)-based fillers with hyaluronidase allows for better management of adverse effects and reversal of suboptimal treatment outcomes. The aim of this study was to compare the enzymatic degradation kinetics of 16 commercially available HA-based fillers, representing 6 manufacturing technologies. In this nonclinical study, a recently developed in vitro multidose hyaluronidase administration protocol was used to induce degradation of HA-based fillers, enabling real-time evaluation of viscoelastic properties under near-static conditions. Each filler was exposed to repeated doses of hyaluronidase at intervals of 5 minutes to reach the degradation threshold of G' ≤ 30 Pa. Noticeable differences in degradation characteristics were observed based on the design and technology of different filler classes. Vycross fillers were the most difficult to degrade and the Cohesive Polydensified Matrix filler was the least difficult to degrade. Preserved Network Technology products demonstrated proportional increases in gel degradation time and enzyme volume required for degradation across the individual resilient hyaluronic acid (RHA) products and indication categories. No obvious relationship was observed between gel degradation characteristics and the individual parameters of HA concentration, HA chain length, or the degree of modification of each filler when analyzed separately; however, a general correlation was identified with certain physicochemical properties. Manufacturing technology was the most important factor influencing the reversibility of an HA product. An understanding of the differential degradation profiles of commercially available fillers will allow clinicians to select products that offer a higher margin of safety due to their preferential reversibility.


  • Open Access

    Strengthening the Key Features of Volumizing Fillers: Projection Capacity and Long-Term Persistence

    by Killian Flégeau, Jing Jing, Camille Vantou, Romain Brusini, François Bourdon, Jimmy Faivre

    Volumizing fillers aim to create or restore facial volume in fat layers. To provide strong tissue lifting and long-term persistence, gels are generally designed with stiff properties, characterized by a high storage modulus (G′). However, clinical evidence shows a discrepancy between high G′ and good lifting capacities, especially after skin tension has been exerted on the gel. To better explore the in vivo behavior of a gel, we first evaluated the elastic moduli of five commercial volumizers (RHA4, JUVVOL, RESVOL, RESLYFT, and BELVOL) in dynamic compression mode, E′. We further developed a Projection Index score based on the rheological assessment of creep in compression to mimic skin tension-induced stress relaxation (flattening). Finally, the ability of a gel to resist enzymatic degradation was analyzed with a multidose approach. Despite similar clinical indications, volumizers exhibited distinct behaviors. RHA4 and BELVOL showed the highest E′ values (resistance to strain), RHA4, JUVVOL, and RESVOL exhibited the greatest projection capacities, while JUVVOL and RHA4 offered the largest persistence to enzymatic degradation. In this article, we introduce the use of the Projection Index to efficiently assess the ability of a gel to lift tissues, thus increasing preclinical models’ efficiency and reducing the need for animal studies.